Lymphoma (includes NHL, HL, CNS Lymphoma)

NICE Recommends Imbruvica For Some MCL Patients

(PharmaTimes [UK]) Dec 15, 2017 - It is looking likely that a subgroup of patients with mantle cell lymphoma (MCL) will get routine access to Janssen’s Imbruvica on the NHS.

read article

Advances in Multiple Myeloma, Lymphoma, and Histiocytosis among Results Presented at 2017 ASH Meeting

(MSK/OnCancer Blog) Dec 12, 2017 - At the 2017 meeting, held December 9 to 12 in Atlanta, Memorial Sloan Kettering researchers reported important progress in the treatment of several blood cancers.

read article

Patients Die as Breakthrough Cancer Drug Reaches Only a Few

(Bloomberg Quint) Dec 14, 2017 - Two months after Gilead Sciences Inc.’s breakthrough treatment was approved in the U.S. to treat a deadly form of blood cancer, only a tiny handful of patients have actually gotten the costly therapy, while others linger on waiting lists.

read article

Strata Oncology Adds Five Healthcare Systems to Strata Precision Oncology Network™

(Markets Insider) Dec 13, 2017 - Strata Oncology, a precision oncology company, today announced five leading healthcare systems have joined the Strata Precision Oncology Network™ (Network). Launched in February of 2017, and led by Strata Oncology, the Network is advancing precision oncology by providing advanced cancer patients routine tumor profiling and matching to a portfolio of biomarker-matched pharma-sponsored clinical trials.

read article

Juno Therapeutics Highlights Data and Presentations Supporting Best-in-Class Strategy for JCAR017 at ASH

(Markets Insider) Dec 12, 2017 - Juno Therapeutics, Inc., a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today highlighted presentations and data from the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, Georgia, December 9-12, 2017.

read article

Spectrum Pharmaceuticals Highlights Two Oral Presentations on FOLOTYN® (pralatrexate injection) at the 59th Annual Meeting of the American Society of Hematology (ASH)

(Yahoo! Finance) Dec 13, 2017 - Spectrum Pharmaceuticals announced two oral presentations of data on FOLOTYN and research progress for the treatment of Peripheral T-Cell Lymphoma (PTCL) at the 59th American Society of Hematology (ASH).

read article

Researchers Develop Test That Can Diagnose Two Cancer Types

(Georgia State University) Dec 12, 2017 - A blood test using infrared spectroscopy can be used to diagnose two types of cancer, lymphoma and melanoma, according to a study led by Georgia State University.

read press release

Chemotherapy-Free Cancer Treatments Move Closer To Reality

(Forbes) Dec 12, 2017 - CAR T-cell treatments continue to achieve impressive results in treating an ever-increasing variety of cancers, but will they ever be able to completely replace chemotherapy?

read article

ASH 2017 Highlights: CAR-T Competition, Myeloma, Hemophilia & More

(Xconomy National) Dec 11, 2017 - The annual American Society of Hematology meeting is nearly over. For now, we’ve chosen updates from three disease areas to highlight, plus the more notable market movements.

read article

Immuno-Oncology Drug Development -- Too Much Of A Good Thing?

(Forbes) Dec 12, 2017 - The annual meeting of the American Society of Hematology (ASH), now wrapping up in Atlanta, has generated a lot of excitement about immuno-oncology treatments like Bluebird Bio and Celgene’s experimental CAR-T targeting multiple myeloma.

read article

Global CAR T Therapy Trial Shows High Rates Of Durable Remission For NHL

(Penn Medicine) Dec 11, 2017 - In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah™ (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients.

read press release

Access and Reimbursement for Adoptive T-Cell Transfer Drugs

(Pharmaceutical Executive) Dec 11, 2017 - Groundbreaking treatments involving adoptive cell transfer, such as CAR -T drugs, call for innovative commercialization strategies.

read article

Increasing Physical Activity Improves Survival In Lymphoma Patients, Mayo Researchers Say

(Mayo Clinic News Network) Dec 12, 2017 - An observational study by researchers at Mayo Clinic has found that increasing physical activity not only decreased the risk of death from all causes but also decreased the risk of death specifically from lymphoma.

read article

Health Disparities May Affect End-of-life Experiences Of Minority Blood Cancer Patients

(Fred Hutch News Service) Dec 11, 2017 - When it comes to cancer, racial minorities face higher barriers to care than do white patients. Now, research shows that those health disparities might extend even to where and how patients die.

read article

Kyowa Hakko Kirin Announces Results of Phase 3 Clinical Study of Mogamulizumab (KW-0761) in Patients with Cutaneous T-cell Lymphoma at the American Society of Hematology 2017

(Kyowa Kirin) Dec 11, 2017 - Kyowa Hakko Kirin Co., Ltd. announced today that the results of the Global Phase 3 study (MAVORIC: Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL) investigating the use of mogamulizumab (KW-0761) in patients with cutaneous T-cell lymphoma (CTCL) will be presented at the Annual Meeting of American Society of Hematology 2017.

read corporate press release

City Of Hope Physicians Report On New CAR-T Cell Therapy For Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm At American Society Of Hematology Annual Meeting

(City Of Hope) Dec 11, 2017 - City of Hope patients whose acute myeloid leukemia (AML) was no longer responding to standard therapies and a patient with a rare blood cancer, blastic plasmacytoid dendritic cell neoplasm, achieved a complete response (cancer-free) after undergoing treatment with MB-102 CAR-T therapy, which targets CD123 cells.

read press release

Daiichi Sankyo Presents Phase 1 Data for EZH1/2 Dual Inhibitor DS-3201 in Patients with Non-Hodgkin Lymphomas at the 59th Annual Meeting of the American Society of Hematology

(Business Insider) Dec 11, 2017 - Daiichi Sankyo Company, Limited today announced that preliminary safety and efficacy data from a phase 1 study of DS-3201, an investigational and potential first-in-class EZH1/2 dual inhibitor, in patients with relapsed or refractory non-Hodgkin lymphomas (NHLs) were presented during a poster session at the 59th Annual Meeting of the American Society of Hematology in Atlanta, Georgia.

read article

Verastem Announces the Presentation of Phase 1 Duvelisib Combination Data in T-Cell Lymphomas at the ASH 2017 Annual Meeting

(Verastem) Dec 11, 2017 - Verastem, Inc. today announced the presentation of new preclinical and Phase 1 clinical data from an investigator-sponsored study evaluating the safety and activity of oral duvelisib in combination with romidepsin (Istodax®) or bortezomib (Velcade®) in relapsed or refractory T-cell lymphomas (TCL) at the American Society of Hematology (ASH) 2017 Annual Meeting held December 9-12, 2017 in Atlanta.

read corporate press release

Miragen Therapeutics Presents New Interim Clinical Data Expanding On Previous Data Suggesting Positive Impact From Systemically Administered MRG-106 On Mycosis Fungoides Form Of Cutaneous T-cell Lymphoma At 2017 American Society Of Hematology Annual Meeting

(Miragen) Dec 11, 2017 - miRagen Therapeutics, Inc. announced today new interim results from its ongoing Phase 1 clinical trial of MRG-106 in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL).

read corporate press release

Gamida Cell Presents Data from Two Key Development Programs at the 2017 ASH Annual Meeting

(Yahoo! Finance) Dec 11, 2017 - Final results from the company’s phase I/II study of NiCord® demonstrate important potential as a universal transplantation solution for patients with high-risk blood cancers; preclinical study of NAM-NK Cells supports utility as an immunotherapeutic modality for treating cancer.

read article
Next Page